Myasthenia gravis induces the activation and maturation of lymphocytes in thymoma

Journal of Clinical Immunology

Volumn 16, Issue 4, 1996, Pages 190-197

  Takahashi, Keiji ^a   Monden, Yasumasa ^a   Saito, Seiya ^a   Kamamura, Yoshitaka ^a   Uyama, Tadashi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Lymphokine activated killer; Myasthenia gravis; Phenotype; Thymoma; Tumor infiltrating lymphocytes

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HUMAN; LYMPHOKINE ACTIVATED KILLER CELL; MALE; MYASTHENIA GRAVIS; PHENOTYPE; PRIORITY JOURNAL; THYMOMA;

ADULT; AGED; ANTIGENS, CD3; ANTIGENS, CD4; CD4-CD8 RATIO; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; HUMANS; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; LYMPHOCYTES; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; THYMOMA; THYMUS NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0029949827     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01541224     Document Type: Article

References (33)

1. Rosai J, Levine GD: Tumors of the Thymus, Atlas of Tumor Pathology. Washington, DC, Armed Forces Institute of Pathology, 1976
2. Brown G, Greaves MF, Lister TA, Rapson H, Papamichael M: Expression of human T and B lymphocyte cell-surface markers on leukemic cells. Lancet 2:753-755, 1474
3. Levine GD, Polliack A: The T-cell nature of lymphocytes in two human epithelial thymomas: A comparative immunogenic scanning and transmission electron microscopic study. Clin Immunol Immunopathol 4:199-208, 1975
4. Crossman J, Deegan MA, Schnitzer B: Thymoma: An immunologic and electron microscopic study. Cancer 41:2183-2191, 1978
5. Lauriolu L, Maggiano N, Marino M, Carbone A, Piantelli M, Misiani P: Human thymoma: Immunologic characteristics of the lymphocytic component. Cancer 48: 1992-1995, 1981
6. Ichikawa Y, Shimizu H, Yoshida M, Arimori S: Two-color flow cytometric analysis of thymic lymphocytes from patients with myasthenia gravis and/or thymoma. Clin Immunol Immunopathol 62:41-96, 1992
7. Fujii Y, Monden Y, Nakahara K, Hashimoto J, Kawashima Y: Antibody to acetylcholine receptor in myasthenia gravis: Production by lymphocytes from thymus or thymoma. Neurology 34: 1182-1186, 1984
8. Shimizu N, Moriyama S, Aoe M, Nakata M, Ando A, Terumoto S: The surgical treatment of invasive thymoma. Resection with vascular reconstruction. J Thorac Cardiovasc Surg 103:414-120, 1992
9. Lewis JE, Wick MR, Scheithauer BW, Bernatz PE, Taylor WF: Thymoma. A clinicopathologic review. Cancer 60:2727-2743, 1987
10. Wilkins EW Jr, Castleman B: A continuing survey at the Massachusetts general hospital. Ann Thorac Surg 28:252-255, 1979
11. De Baect M, Einarson J, Lindstorm JM, Weigle W: Lymphocyte activation in experimental autoimmune myasthenia gravis. J Immunol 128:2228-2265, 1982
12. Limburg PC, Hummel-Tappel E, Oosterhuis HJ, The TH: In vitro T-cell dependent B-cell activity in myasthenia gravis. Clin Exp Immunol 61:31-38, 1985
13. Christadoss P, Lindstorm JM, Talal N, Duvic CR, Kalantri A, Shenoy M: Immune response gene control of lymphocyte proliferation induced by acetylcholine receptor. Specific helper factor derived from lymphocytes of myasthenic mice. J Immunol 137: 1845-1849, 1986
14. Cohen-Kaminsky S, Gaud C, Morel E, Berrin-Aknin S: High recombinant interleukin-2 sensitivity of peripheral blood lymphocytes trom patients with myasthenia gravis: Correlations with clinical parameters. J Autoimmun 2:241-258, 1989
15. Cohen-Kaminsky S, Levasseur P, Binet JP, Berrin-Aknin S: Evidence of enhanced recombinant interleukin-2 sensitivity in thymic lymphocytes from patients with myasthenia gravis: Possible role in autoimmune pathogenesis. J Neuroimmunol 24:75-85, 1989
16. Lander I, Ahern EW: The significance of lymphocytic infiltration and prognosis in colorectul carcinoma. Br J Cancer 49:375-377, 1985
17. Wolf GT, Hudson JL, Peterson KA, Miller HL, McClatchey KD: Lymphocyte suhpopulations infiltrating squamous carcinomas of the head and neck: Correlations with extent of tumor and prognosis. Otolaryngol Head Neck Surg 95:142-152, 1986
18. Ferradini L, Miescher S, Streck M, Busson P, Cerf-Bensussan N, Lipinskim M, von-Fliedner V, Tursz T: Cytotoxic potential despite impaired activation pathway in T lymphocytes infiltrating nasopharyngeal carcinoma. Int J Cancer 47:362-370, 1991
19. Ioannides CG, Plastsoucas CD, Rashed S, Wharton JT, Edwards CL, Freedman RS: Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res 51:4257-4265, 1991
20. Kato K, Yamada T, Onda H, Asano T, Sagino H, Kakimura A: Purification and characterization of recombinant human interleukin-2 produced in Escherichia coli. Biochem Biophys Res 31:692-699, 1985
21. Takahashi K, Sone S, Saito S, Kamamura Y, Uyama T, Ogura T, Monden Y: Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion. Jpn J Cancer Res 86:861-866, 1995
22. Takahashi K, Sone S, Kimura S, Ogura T, Monden Y: Pehtnotypes and lymphokine-activated killer activity of pleural cavity lymphocytes of lung cancer patients without malignant effusion. Chest 103:1732-1738, 1993
23. Namba T, Brunner NG, Grob D: Myasthenia gravis in patients with thymoma, with particular reference to onset after thymectomy. Medicine 57:411-433, 1978
24. Monden Y, Nakahara K, Kogatani K, Fujii Y, Masaoka A, Kawashima Y: Myasthenia gravis with thymoma: Analysis of and postoperative prognosis for 65 patients with thymomatous myasthema gravis. Ann Thorac Surg 38:46-52, 1984
25. Legg MA, Brady WJ: Pathology and clinical behavior of thymomas: A survey of 51 cases. Cancer 18:1131-1144, 1965
26. Weissberg D, Goldberg M, Pearson FG: Thymoma. Ann Thorac Surg 16:141-147, 1973
27. Gray GF, Gutowski WT: Thymoma: A clinicopathologic study of 54 cases. Am J Surg Pathol 3:235-249, 1979
28. Torten M, Sidell N, Golub SH: Interleukin 2 and stimulator lymphoblastoid cells will induced human thymocytes to hind and kill K562 targets. J Exp Med 156:1545-1505, 1982
29. Toribio ML, Landazuri MO, Lopez-Botet M: Induction of natural killer-like cytotoxicity in cultured human thymocytes. Eur J Immunol 13:964-969, 1983
30. Lopez-Botet M, Moretta L: Functional characterization of human thymocytes: A limiting dilution analysis of precursors with proliferative and cytolytic activities. J Immunol 134:2299-2304, 1985
31. Blue M, Levine H, Daley JF, Craig KA, Schlosstnan F: Development of natural killer cells in human thymocytes culture: Regulation by accessory cells. Eur J Immunol 17:669-673, 1987
32. Lanier LL, Benike CJ, Phillips JH, Engleman EG: Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu II antigens. J Immunol 134:794-801, 1985
33. + lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL-2)-induced activated killer (AK) cells. J Immunol 134:802-807, 1985